Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

11.00 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,683
Open 11.00
Bid (Size) 10.82 (500)
Ask (Size) 10.93 (100)
Prev. Close 11.00
Today's Range 11.00 - 11.00
52wk Range 1.760 - 11.13
Shares Outstanding 305,252,194
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why Iovance Biotherapeutics Stock Was on Fire Today ↗
An influential investment bank resumed its coverage of the company. 
Via The Motley Fool
News headline image
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains ↗
Iovance Biotherapeutics (NASDAQ:IOVA) said it is expanding its tumor-infiltrating lymphocyte, or TIL, therapy platform across multiple solid-tumor indications after reporting a record second quarter... 
Via MarketBeat

Performance

YTD
+336.5%
+336.5%
1 Month
+37.3%
+37.3%
3 Month
+161.3%
+161.3%
6 Month
+231.3%
+231.3%
1 Year
+393.3%
+393.3%

More News

Read More
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics (NASDAQ:IOVA) Beats Q2 Estimates on Record Revenue, Shares Jump ↗
Via Chartmill
IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) Passes Mark Minervini’s Trend Template and High-Growth Momentum Screen ↗
Via Chartmill
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance (IOVA) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher? ↗
Via The Motley Fool
News headline image
Iovance Biotherapeutics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
Top stock movements in today's session. ↗
Via Chartmill
News headline image
Iovance (IOVA) Stock Soars After Better-Than-Expected Q2 Results ↗
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
This Stock Is Up 74% This Year: Is It Too Late to Buy? ↗
Via The Motley Fool
News headline image
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
From Biotech Insider
Via GlobeNewswire
News headline image
Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For? ↗
Via The Motley Fool
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances Delivery-Focused Oncology Platform Amid Growing Interest in Drug-Delivery Technologies
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
Via Investor Brand Network

Frequently Asked Questions

Is Iovance Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, Iovance Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does Iovance Biotherapeutics, Inc. - Common Stock trade on?
Iovance Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock?
The ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock is IOVA on the Nasdaq Stock Market
What is the current price of Iovance Biotherapeutics, Inc. - Common Stock?
The current price of Iovance Biotherapeutics, Inc. - Common Stock is 11.00
When was Iovance Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Iovance Biotherapeutics, Inc. - Common Stock was at 09/25/26 04:00 PM ET
What is the market capitalization of Iovance Biotherapeutics, Inc. - Common Stock?
The market capitalization of Iovance Biotherapeutics, Inc. - Common Stock is 3.36B
How many shares of Iovance Biotherapeutics, Inc. - Common Stock are outstanding?
Iovance Biotherapeutics, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.